Phase II Clinical Trial of NV-387 Oral Gummies as Treatment of Ebola Progressing Well, Says NanoViricides
NanoViricides said its Phase IIA Ebola trial of NV-387 Oral Gummies in the DRC Bundibugyo outbreak is progressing well and continuing to enroll across disease severity levels. The exploratory trial of up to 20 subjects evaluates safety and tolerability of 6-12 days of dosing, with no control arm; an efficacy signal could emerge if the treated group is discriminated from the 67-75% background infection-to-fatality rate. Formal results will come only after trial completion and the Principal Investigator's report, which will determine advancement into a randomized, controlled Phase IIB.
Key figures
- Drug Name
- NV-387 Oral Gummies
- Phase Of Trial
- Phase IIA
- Drc deaths
- 4339
- Cfr percent
- 48%
- Ifr percent
- 67-75%
- Dosing duration
- 6 days starting, extending by 3-day increments to max 12 days
- Trial subjects max
- 20
- Drc confirmed cases
- 9000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.